Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and
clinically heterogeneous diseases that cannot be further classified into any other of the …

Patients with relapsed or refractory peripheral T-cell lymphoma display a dismal prognosis
and their therapy represents an unmet medical need, as the best treatment strategy is yet to …

An angioimmunoblastic lymphadenopathy with dysproteinemia was first described by the
group of Henry Rappaport in the 1970s. 1 At that time, it was not recognized as a malignant …

Introduction Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS) is a rare,
highly heterogeneous group of mature T‐cell neoplasms that historically has been …

A significant proportion of patients with T-cell lymphoma relapse after induction or are
refractory to treatments. Therefore, there is an urgent need to develop new drugs with …

Keywords: brentuximab vedotin; novel agents; peripheral T-cell lymphomas; refractory;
relapsed EN brentuximab vedotin novel agents peripheral T-cell lymphomas refractory …

Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is the most common
subgroup of peripheral T-cell lymphomas (PTCL), and constitutes a diagnosis of exclusion …

Background. The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the
most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately …

Common T-cell leukemias/lymphomas frequently involving the spleen and liver include
entities such as T-cell prolymphocytic leukemia, aggressive NK-cell leukemia, and …